Viking Therapeutics announced positive top-line results from its maintenance study of VK2735, a GLP-1/GIP agonist for obesity. The study demonstrated that patients maintained significant weight loss after switching from weekly injections to less frequent dosing regimens, including every-other-week and monthly administrations, while showing favorable tolerability.
Key Details
- Weight Loss Maintenance: Patients switching to every-other-week dosing maintained up to 97% of their initial weight loss, while those on monthly dosing maintained up to 90%. This was significantly better than the placebo group, which maintained only 61%.
- Induction Phase Efficacy: An exploratory control group continuing weekly dosing of VK2735 at 17.5 mg showed a mean weight loss of approximately 22% from baseline after 33 weeks, with no plateau observed.
- Safety and Tolerability: During the 12-week maintenance period, VK2735 was well-tolerated, with rates of gastrointestinal (GI) adverse events similar to placebo and low rates of discontinuation due to adverse events.